Loxoprofen

Drug Profile

Loxoprofen

Alternative Names: CS-600G; Loxonin; Loxonin Pap; Loxonin Tape; Loxoprofen gel; Loxoprofen poultice; Loxoprofen sodium; Loxoprofen tape; LX-A; LX-P

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Cardinal Health; Daiichi Sankyo Brasil; Daiichi Sankyo Company; Lead Chemical
  • Class Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 01 Dec 2016 Daiichi Sankyo Brasil Farmacêutica completes a phase III trial in Pain in Brazil (Transdermal, Patch) (NCT02616068)
  • 01 Dec 2015 Lead Chemical completes a phase II trial in Pain (In volunteers) in USA (Transdermal) (NCT02602353)
  • 13 Oct 2015 Launched for Pain in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top